iRGD肽
iRGD肽 性质
| 密度 | 1.68±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | -20°C, protect from light |
| 溶解度 | DMSO: Soluble: =10 mg/mlPBS (pH 7.2): Soluble: =10 mg/ml |
| 形态 | 固体 |
| 酸度系数(pKa) | 2.92±0.70(Predicted) |
| 颜色 | 白色至米白色 |
| 水溶解性 | Water : ≥ 50 mg/mL (52.74 mM) |
| 序列 | H-Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys-OH(Disulfide bridge: Cys1-Cys9) |
iRGD肽 用途与合成方法
Integrin
iRGD peptide-mediated tumor penetration occurs in three steps: binding to αv-integrins on tumor vasculature or tumor cells, exposure by proteolysis of a C-terminal motif that binds to neuropilin-1 (NRP-1) and cell internalization. iRGD peptide inserted in the ICOVIR15K fiber C terminus enhances binding and internalization only in MCF7 cells, which express NRP-1 and integrins. iRGD insertion does not impair virus infection and replication. iRGD peptide alone has no obvious effect on gastric cancer cells, and when combined with 5-FU, iRGD peptide (0.3 μmol/mL) enhances the chemotherapy efficacy of 5-FU on gastric cancer cells through NRP1.
iRGD inserted in the oncolytic adenovirus ICOVIR15K (ICOVIR15K-iRGD) enhances early adenovirus dissemination through the tumor mass and elevates the antitumor effect in mice. iRGD (4 mmol/kg, i.v.) in combination with 5-FU significantly suppresses the tumor growth in nude mice bearing human gastric cancer cells.
纯度(HPLC) ≥98.0%
醋酸根含量≤12.0%
水分含量≤8.0%
肽含量≥80.0%
内毒素≤50EU/mg
氨基酸组成分析≤±10%
